Top segments and regional performance

Last year, the company generated 450.71 M USD, the most of which — 450.71 M USD — came from its top-performing segment, Oral Small-molecule and Injectable Protein Therapeutics, compared to 331.41 M USD the previous year. The greatest contribution came from United States, which accounted for 385.96 M USD last year, with 288.36 M USD the year before.